

Hereditary Lifetime Cancer Risk Assessment Modeling: A Case Study in Breast Cancer

Martínez-Ávila JC^{1*}, Guillén-Ponce C², Earl J² and García-Cortés LA³

¹Health Research Institute "Hospital 12 de Octubre" SCReN, CIBERESP, Spain

²Medical Oncology Department, Hospital Universitario Ramón y Cajal, Carretera Colmenar Viejo KM 9, Madrid, Spain

³Animal Breeding and Genetics department, INIA(Instituto Nacional de Investigaciones Agrarias y Tecnología Alimentaria), Ctra de la Coruña KM 7, Madrid, Spain

*Corresponding author: Jose Carlos Martinez Avila, Health Research Institute "Hospital 12 de Octubre" SCReN (Spanish Clinical Research Network) CIBERESP (Biomedical Research Centre Network for Epidemiology and Public Health), Avda de Cordoba s/n, Edificio de actividades ambulatorias 6D, Madrid, Spain, E-mail: Jcmartineza.imas12@h12o.es

Received date: 17 Aug 2016; Accepted date: 28 Sep 2016; Published date: 04 Oct 2016.

Citation: Martínez-Ávila JC, Guillén-Ponce C, Earl J, García-Cortés LA (2016) Hereditary Lifetime Cancer Risk Assessment Modeling: A Case Study in Breast Cancer. *Int J Mol Genet and Gene Ther* 2(1): doi <http://dx.doi.org/10.16966/2471-4968.106>

Copyright: © 2016 Martínez-Ávila JC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

It is not straightforward to assess an individual genetic cancer risk in order to provide accurate and effective genetic counseling and secondary screening.

We present an analysis of the Minnesota Breast Cancer data based on the Best Linear Unbiased Prediction (BLUP) methodology to estimate an individual's predicted genetic risk of developing cancer during their lifetime. The model uses cancer status, year of birth (yob), sex, age at last follow-up (endage) and number of births (parity) to estimate variance components in order to define heritability. This tool that can also be applied to determine whether aggregation of cancer within a family is indeed due to heritability or due to shared environmental factors. We provide an example of how this model can be used in the context of breast cancer but it can be applied to many cancer types with a genetic component.

We have obtained a reliable estimation of heritability for cancer (breast and prostate) between 0.1-0.2, different from zero, and meaningful additive values of cancer in the Minnesota Breast data set for each individual. BLUP is able to incorporate clinical and pathological information in the estimations and consider a polygenic inheritance model instead of an autosomal dominant model.

BLUP provides an additional tool for use in hereditary cancer and estimates the extent of heritability of cancer, calculating an individual genetic risk of cancer in family members and an approximation of the genetic risk of future descendants. In addition this tool can be used to assess the genetic basis of hereditary cancer in these families, either due to high risk alleles for low-medium risk alleles.

Keywords: Best linear unbiased prediction; Additive genetic effect; Minnesota breast cancer-heritability; Genetic risk; Cancer risk assessment; Predictive models of cancer risk; Expected genetic values

Abbreviations: BLUP: Best Linear Unbiased Prediction; ROH: Runs of Homozygosity; HPDI: High Posterior Density Interval; EGV: Expected Genetic Value; ROC: Receiver Operating Characteristic; AUC: Area under the ROC Curve.

Introduction

Approximately 5-10% of all cancers have a hereditary component [1] and 9.4% of breast cancer cases have an affected first degree relative [2]. The presence of a pathogenic germline mutation in a known cancer gene means that this individual has a greater probability of developing a particular cancer type(s) during their lifetime. However, there is undoubtedly a large difference in cancer susceptibility depending upon the inheritance of different genetic variants and how these variants interact and in the genomic era we are discovering more genes and gene variants that are involved in complex diseases such as cancer [3,4]. High risk genes are present at a low frequency in the general population while medium-lower risk genes appear at a higher frequency. In the absence of a known pathogenic germline mutation it is difficult to assess cancer risk especially when subjects harbor variants of unknown significance in these genes. There are still many medium-low risk alleles occurring at a high frequency that are still unknown as well as their effect to modify the development of cancer and there is an ongoing effort to decipher their contribution to cancer risk [5]. On the other hand in order to discover "soloist" genes we need to know how much of the phenotypic variation that we see is due to genetics.

A cancer is usually considered as sporadic cancer unless the patient has characteristics associated with familial cancer such as additional cancer cases within the family, an unusually early age at diagnosis, multiple tumors in the same individual such as bilateral tumors or different but related tumors such as breast and ovarian cancer. Guidelines for genetic and high risk assessment in these types of families include the National Cancer Comprehensive Network and NICE [6,7] among others.

In the particular case of breast cancer, around 25-30% of heritability can be attributed to mutations in the high to moderate risk genes (*BRCA1*, *BRCA2*, *CHEK2*, *ATM*, *PALB2*, *PALB1*, *BRIPI*, *TP53*, *PTEN*, *CDH1* and *STK11*) [5,8]. The majority of these genes are involved in DNA repair and the regulation of cell-cycle checkpoints in response to DNA damage. Other low-moderate risk genes include *BARD1*, *RAD51C* and *RAD51D* [9-11]. Disease susceptibility in non-mutation carriers could be explained by a polygenic model where many susceptibility genes and polymorphisms within these genes combine to increase risk and produce the observed cancer phenotype [12]. Recent efforts in breast cancer research aim to discover the effect of rare alleles via high density next generation sequencing and coordinating international research groups into consortia [13].

Despite the fact that high quality pedigree information in humans is rare, mainly due to small family size, lack of clinical records or non-informative pedigrees, when it is recorded, a new opportunity arises to learn more about the genetic basis of cancer. The statistical definition of heritability is defined as the proportion of phenotypic variance attributable to genetic variance. When the variation explained by genetics is small, there is a need for accurate statistical methods to find individual genes.

In order to estimate an individual lifetime risk of developing breast cancer, family history and personal information have been combined in several statistical models under different assumptions. The Claus model focuses on Caucasians with an unknown germline mutation and information of first or second degree female relatives with breast cancer [14]. The Gail model is based on a multivariate logistic regression model in order to estimate breast cancer risk [15-17]. In this case the Gail model includes only information of the first-degree relatives and gives more importance to affected individuals. This feature of the Gail model may underestimate breast cancer risk in case of large family history of breast [18,19].

The likelihood that a *BRCA1* or *BRCA2* mutation is present is calculated using different approaches, among others, BRCAPRO and Breast and Ovarian Analysis of Disease incidence and Carrier Estimation Algorithm (BOADICEA) [20,21]. Some guidelines such as the American Cancer Society (ACS) guidelines on breast screening to identify a woman as being at high risk of breast cancer [22,23] use models based on family history which assess between 20–25% of lifetime risk for breast cancer or greater.

The Best Linear Unbiased Prediction (BLUP) Model [24] has been one of the most useful tools in animal and plant breeding with regard to the study of complex traits and nowadays this methodology is of interest to human diseases such as hereditary cancer [25]. The BLUP methodology provides an individual predicted genetic risk [26] which can be used to assess an individual's risk of developing cancer during their lifetime which is important for genetic counseling in familial cancer, particularly in families with an unknown genetic basis. These subjects can be further studied in order to find medium-low risk alleles.

The Minnesota data breast cancer family is a historical cohort study of relatives of a consecutive series of 426 breast cancer cases, proband, identified between 1944 and 1952 [27] and have been used in familial clustering research of breast and prostate cancer [28]. The data set contains information with regard to affected status, sex, age, year of birth, father, mother, family, age at last follow up, education status, marital status, number of pregnancies and number of births.

We have used the Minnesota data breast cancer family with the aim to a) apply the BLUP methodology to estimate heritability in breast cancer in order to determine how much of the variation is due to genetic inheritance; b) propose a new individual measure for assigning a genetic additive value of cancer risk in families with a family history which is comparable with other genetic risk assessment models; c) develop an algorithm that can be used to identify individuals with a high cancer additive risk and thus aid in prioritizing families for genetic testing and/or the identification of novel genes and polymorphisms associated with cancer.

Materials and Methods

Data

The Minnesota data breast cancer family study is available free in the R package kinship2 [29] where functions are provided to calculate a correlation matrix based on identity by descent and pedigree. The data consists of 20532 individuals of 426 families, one proband per family and a pedigree with 28082 individuals, 20532 with usable data.

1224 females presented with breast cancer.

The outcome variable is binary, assigning a value of 1 to an individual suffering cancer and a value of 0 for no cancer. When a binary trait is under study we assume an underlying continuous random variable that is normally distributed with a variance equal to one (liability). A threshold in this liability indicates when we have a case, is to say, cancer or no cancer.

From the Minnesota data, subject identifier (id), identifier of the father (fatherid), identifier of the mother (motherid), and sex were used to build a pedigree. Cancer, year of birth (yob), family identifier (family), sex, age at last follow-up (endage) and number of births (parity) were retained for the mixed model.

Year of birth, with amplitude of yob more than one century from 1842 to 1983, was used in two different ways, centered in 1920 and added as covariate in a polynomial of degree 3 or as random effect. The reason for this is to check if there could be a random environmental effect of yob (model 1) or not (model 2).

Missing values in sex, year of birth, parity and endage represent 0.07%, 23.92%, 3.36% and 32.65% of the total number of observations respectively. These values were imputed using a random forest function.

Cancer incidence per family was calculated as the number of affected individuals in the family divided by the total number of family members with cancer record available. In order to avoid the inclusion of artificial noise due to imputation, we decided not to use more explanatory variables since they have a high missing rate.

This data base was established at the 40,s last century and unfortunately there is no information regarding BRAC mutations.

Statistical methodology to assess an individual's risk of developing cancer during their lifetime

Statistical analysis was performed using R [30] and packages MCMCglmm [31], kinship2 [29], missForest [32] and ROCR [33]. MCMCglmm was used to sample from mixed models equations and variance components. The kinship2 package was used for pedigree plots, and the ROCR package for ROC curves plot calculations. Finally, missForest, was used to impute continuous and categorical data allowing for non-linear relations and complex iterations

Best Linear Unbiased Prediction (BLUP): The methodological aspects were based on BLUP through Henderson's mixed model equations approach [24] and Fisher's infinitesimal model [34].

Given a linear mixed model,

$$y = X\beta + Zu + e$$

Where y is the observed phenotype, β and u is vectors of fixed and random effects, X and Z are design matrices and e is the random error.

Random effects are defined as multivariate normal distributed, MVN , $u \sim MVN(0, G)$ and $e \sim MVB(0, R)$ with G - genetic variance covariance matrix and R - residual variance covariance matrix.

The solution to the previous model was pointed by Henderson,

$$\begin{bmatrix} X'R^{-1}X & X'R^{-1}Z \\ Z'R^{-1}X & Z'R^{-1}Z + G^{-1} \end{bmatrix} \begin{bmatrix} \hat{\beta} \\ \hat{u} \end{bmatrix} = \begin{bmatrix} X'R^{-1}y \\ Z'R^{-1}y \end{bmatrix}$$

In Fisher's infinitesimal model, the genetic inheritance is based on infinite loci with a small additive effect. This genetic inheritance modified by the environment produces the observed phenotype, BLUP methodology allows us to calculate this additive part of the genetic inheritance.

The broad-sense heritability is the fraction of phenotypic variance attributable to genetic variation. When average affects, additive, of this genetic variation are taken into account, the narrow sense heritability is defined.

In this study the term heritability is defined as the additive component of the genetic variation.

Two models have been proposed and fitted which differ in the inclusion of yob as a random (model 1) or fixed effect (model 2).

In a previous variable selection step based on a generalized logistic model and according with the available information, family as a variable was discarded from the model and only sex, endage, parity and yob were retained as explanatory variables.

Model 1

$$\text{Cancer} \square \mu + \text{sex} + \text{endage} + \text{parity} + \text{yob} + \text{yob}^2 + \text{yob}^3 + \text{individual}$$

with $YOB \square N(0, I\sigma_{yob}^2)$ and $\text{individual} \square (0, A\sigma_{\text{individual}}^2)$ where I is the identity matrix, A the numerator relationship matrix whose elements are twice the coancestry between individuals [35], σ_{yob}^2 the variance given by the year of birth and $\sigma_{\text{individual}}^2$ the genetic additive variance.

Model 2

$$\text{Cancer} \square \mu + \text{sex} + \text{endage} + \text{parity} + \text{yob} + \text{yob}^2 + \text{yob}^3 + \text{individual}$$

with yob as a covariate and $\text{individual} \square N(0, A\sigma_{\text{individual}}^2)$ where, is A the numerator relationship matrix, and $\sigma_{\text{individual}}^2$ the genetic additive variance.

Both models consider that $R=I$, that is, there is no residual covariance between records.

Heritability estimations: Heritability was calculated to assess the additive component of the genetic variation and was calculated as follows,

$$h^2 = \frac{\sigma_{\text{individual}}^2}{\sigma_{\text{individual}}^2 + \sigma_{yob}^2 + 1} \text{ in model 1 and } h^2 = \frac{\sigma_{\text{individual}}^2}{\sigma_{\text{individual}}^2 + 1} \text{ in model 2}$$

The consistency of our estimations for h^2 was evaluated by testing the null hypothesis, $H_0 (h^2=0/data)$, on the heritability using a Bayes factor against the null hypothesis calculating the marginal posterior density following the method proposed by García-Cortés et al. [36]. This method examines the posterior density of $h^2=0$ and calculates the probability of the alternative hypothesis (additive component) as,

$$p(H_1/data) = \frac{1}{1 + p(h^2/data)} \quad (1)$$

and the probability of the null hypothesis (no additive component),

$$p(H_0/data) = \frac{p(h^2=0/data)}{1 + p(h^2=0/data)} \quad (2)$$

Estimation of expected genetic values EGVs: Expected genetic values (EGVs) are solutions of the individual random effect, $u \square MVN(0, G)$, which are different for individuals with cancer or not. The estimation of EGV values requires the solving of the mixed model equations in Best Linear Unbiased Prediction (BLUP) section and the estimation of the variance components in Heritability estimations section. We use Bayesian inference since our outcome is dichotomous and Markov chain Monte Carlo methods have demonstrated their high performance when a binary response is the dependent variable [37]. Non parametric Kruskal Wallis test was used to assess differences in EGVs between outcome groups.

Both models, 1 and 2, were run with 151500 iterations, burning 1500 and chain was sampled every 150 iterations. Inverse Wishart with parameter expansion was assumed as prior for random effects and residual variance was fixed to one, $\sigma_e^2 = 1$.

Converge diagnostics were assessed using Heidelberger and Welch's test [38] in order to accept or reject the null hypothesis, the Markov chain come from a stationary distribution.

Finally in order to develop an algorithm that can be used to identify individuals with a high cancer genetic additive risk, even if we only have the pedigree and no clinical or demographic data, at the time of genetic evaluation we calculated the parental mean of EGV as a proxy of an individual EGV [39] since an individual receives half of their genetic additive inheritance from the mother and the other half from the father. Area under the Receiving Operating Curve (ROC) was used to assess the prediction ability of EGV.

Comparison of the Gail and Claus Models with BLUP to assess cancer risk

For the 9 families with the largest cancer incidence rate we have also calculated the individual risk to develop breast cancer at 5 years using the Gail model [15] and the Claus model [14] using only the available information of Minnesota Breast Cancer. The variables used for the Gail model were age and number of first degree relatives affected with Breast cancer and for the Claus model; age and relationship between proband and affected relatives. These values were compared using the Pearson correlation coefficient with the corresponding EGV.

Assessment of the hereditary component of cancer risk based on EGV

Individuals with EGV values below zero were classified as having no genetic risk of cancer whereas those with a positive value were classified as having a hereditary basis. Families with 1 or 2 cancer cases were assumed as sporadic and not having a hereditary component whereas families with 3 or more cases were thought to have a hereditary component. We calculated summary statistics of EGV for these two groups of families including the mean, median and 25 and 75 percentiles and we used these values to classify the families as having a hereditary component and no hereditary component (i.e sporadic).

Results

Variance component and heritability estimations

The outputs of Heidelberger and Welch's test are presented in additional files (see online resources Tables ESM1 and ESM2) Model 1 and 2 reached convergence implying that our results are valid.

High posterior density intervals, HPDI provided by MCMCglmm, of variance components in Model 1 are [0.018-0.621] and [1.45-2.97] for $\sigma_{\text{individual}}^2$ and σ_{yob}^2 , respectively. In Model 2 HPDI for $\sigma_{\text{individual}}^2$ is [0.057-0.65] which is similar to the interval obtained in Model 1.

This similarity is highlighted (see Online resources Table ESM3) where the mean and standard deviation of estimates are presented. $\sigma_{\text{individual}}^2$ has a similar value in both models.

There is an additive component in cancer genetics which with regard to the Minnesota Breast Cancer data set results in heritability of 0.1 or 0.24 depending on the model specification.

HPDI for heritability is (0.017-0.174) in Model 1 and (0.058-0.396) in Model 2, in both cases HPDI did not include zero, meaning that our results are valid.

Posterior distributions for variance components in both models are presented in additional files (see online resources Figures ESM1 and

ESM2). After equations 1 and 2, the test on the null hypothesis of $H_0 (h^2 = 0)$, results in the rejection of H_0 with ($H_0=0$). It can be observed that posterior density at $h^2 = 0$ is null in both cases (Figure 1).

Descriptive statistics of the Minnesota Breast Cancer families

Table 1 presents descriptive statistics of cancer incidence, year of birth and end age for subjects of the 426 families included in the analysis, there are no significant differences in these variables between male and female subjects. Figure 2 presents cancer incidence in these families, and clearly shows that this increases steadily with the number affected cases in the family. To describe all the pedigrees is unfeasible in a paper, for this reason we present descriptive statistics of incidence, yob, number of cases, end age and sex of the 9 families with the largest and lowest incidence rate in tables 2 and 3 respectively.

Table 2 shows the descriptive statistics of the 9 families with the largest cancer incidence rate. Figure 3 presents pedigrees of these families, with their EGV calculated using model 1.

Expected Genetic Value (EGV)

The EGV provides a measure of genetic additive risk of cancer development as exp (EGVs). Non-affected individuals are expected to have smaller and less dispersed EGVs than those affected by cancer that are larger and spread over a wider range. EGVs have interesting features. First EGVs separate non-affected versus cancer patients. Second they assess an individual genetic value for each individual, the larger the EGV the higher the probability to develop cancer and these EGVs are passed




Figure 1: Heritability density with model 1, red, and model 2, blue.

	Females	Males
Cancer Incidence	0.103	0.016
End age	65.2(16.4)	61.7(13.6)
Year of birth	1924(21)	1923(22)

Table 1: Descriptive statistics by gender Standard deviations in brackets

Family	Incidence	Mean yob	Cases	Females	Males	End age
574	0.33	1932	3	6	5	48.2(12.6)
173	0.28	1913	10	19	17	73.1(13.5)
447	0.24	1916	5	13	11	65.1(17.4)
289	0.23	1914	3	8	7	59.5(17.8)
411	0.23	1933	6	14	20	56.8(11.1)
494	0.22	1921	9	22	24	68.1(15)
19	0.20	1911	5	12	12	70.5(11.9)
474	0.20	1919	9	22	28	72(11.9)
62	0.16	1926	4	15	16	61.8(20.7)

Table 2: Descriptive statistics of the 9 families with largest cancer incidence rate Standard deviations in brackets

Family	Incidence	Mean yob	Cases	Females	Males	End age
397	0.019	1934	1	27	33	62.3(13)
316	0.019	1926	2	73	73	68.6(13.3)
343	0.018	1933	1	36	35	58.5(13.2)
395	0.017	1936	1	39	39	55.5(16.8)
453	0.014	1909	1	49	54	72.2(13.1)
12	0.013	1926	1	46	51	66.4(16.5)
286	0.0129	1907	1	47	48	64.9(16.1)
433	0.0128	1930	1	53	54	61.1(14.8)
274	0.0125	1901	1	40	44	69.5(18.2)
353	0.0120	1913	1	48	46	68.5(16.9)

Table 3: Descriptive statistics of the 10 families with lowest cancer incidence rate Standard deviations in brackets




Figure 2: Cancer incidence per family, calculated as the ratio of the number of cases per family and the number of individuals, against number of cancer cases in the family.

to the next generation. The genetic additive cancer risk can be calculated as the exponential of EGVs. Figure 4 shows the differences in EGVs between cancer affected and non-affected family members using model 1. A similar figure is provided as additional files for model 2 (see Online resources Figure ESM3).

The EGV of cancer cases is higher than healthy individuals (Figure 4a) and this reached statistical significance ($p < 0,001$) (Figure 4b). The EGV for healthy individuals were similar for males and females, whereas the EGV was higher for male cancer cases versus female cancer cases (Figure 4c).

Figure 4d shows the distribution of EGVs for affected (green) and non-affected (red) individuals. Individuals with a positive EGV have a genetic predisposition to cancer develop (marked by the dashed line) and these individuals are likely to harbor mutations or polymorphisms that increase cancer risk. EGVs were compared with cancer status to check predictive performance using ROC curves. These ROC curves and 95 % confidence intervals of area under the ROC curve (AUC) were drawn (see online resources Figure ESM4). Model 1 and 2 show similar large AUC values, 0.93-0.94, therefore when an individual has a high positive EGV this indicates a high genetic predisposition to cancer in comparison with those which have a large negative EGV.

These features explain how EGVs and the observed phenotype are linked and on the other hand the biological meaning of EGVs.


Since an EGV of an individual is $\frac{1}{2}$ of the father's EGV plus $\frac{1}{2}$ of the mother's EGV, we predicted the cancer status using this parental mean and we used this value as a proxy of individual EGV (Figure 5a). The prediction ability of these mean values tested with the corresponding AUC, with a good AUC performance of 0.713-0.791 (Figure 5b).




Comparison of BLUP with Gail and Claus models

Figure 6 provides a comparison between the BLUP genetic risk estimation and the Gail model where risk values are plotted and there was a statistically significant correlation of 0.6 [0.44-0.73] $p < 0.01$ between the two values. In addition, correlation between BLUP genetic risk estimation and cumulative probability of Breast cancer under the Claus model [14] gives a significant correlation of 0.23 [0.02-0.42].


Classification of families and individuals with hereditary and non-hereditary cancer

In figure 7 we show the number of individuals in a family with a positive EGV (i.e. a genetic predisposition to cancer). We can distinguish between families with several members with a positive EGV that are likely to harbor medium-high risk alleles (right hand side of dashed line) from those that have a few members with positive EGV and thus are likely to harbor low-medium risk alleles with a variable penetrance (left hand side of dashed line).





The median EGV for families with 1 or 2 cancer cases (which would normally be considered as sporadic) was -0.23 (-0.25, -0.21, 25 and 75 percentiles respectively), whereas the median EGV of families with 3 or more cases (which depending on the relationship of affected individual's would be considered as having a hereditary component) was -0.18 (-0.21, -0.15, 25 and 75 percentiles respectively) (Figure 7b) The median EGV is significantly higher in families with 3 or more cases (-0.18) than families with 1 or 2 cases ($p < 0.001$). As demonstrated in figure 7c we have used these values as criteria to classify and define families as sporadic or with a hereditary component. We have classified those families with



an EGV below the median value of families with 1-2 cases as sporadic cancer families. The families with a hereditary component are defined as those with an EGV above the 75th percentile of the EGV of families with only 1 or 2 cases. We further define the families with a hereditary component into those that are likely to harbor high risk alleles such as *BRCA2* mutations, i.e. those with an EGV greater than the 75th percentile of the EGV of families with 3 or more cases. As well as families that are likely to harbor low-medium risk alleles, i.e. those with an EGV between the 75th percentile of families with 1 or 2 cases and the 75th percentile of families with 3 or more cases. It is of note that there are families with 3-5 cases of cancer that have median EGV in the sporadic cancer range. The clustering of cancer in these families does not appear to have a hereditary component and may be due to a shared environmental risk factor. Thus genetic testing in these families would be inappropriate and this model

provides a tool to assess the hereditary component in these families before deciding on genetic testing.

Discussion

The BLUP model heritability value applied in this study of families with breast cancer differs from zero and highlights the validity of the polygenic inheritance pattern. EGV are able to discriminate between cancer and no cancer subjects and provides a tool for hereditary cancer counseling since they provide an individual risk assessment even if the patient has not yet developed cancer. Given the binary nature of the outcome, the results presented in this paper are reliable and accurate.

EGV can be estimated more precisely by adding clinical, pathological and socio-demographic data; however these data are not usually available. Data with regard to the presence of germline mutations in susceptibility genes can be easily incorporated at a later stage into the model as it becomes available. Indeed, genomic information could be used in combination with the pedigree or alone to calculate a more accurate relationship matrix [40]. Moreover, even if a family tree cannot be constructed due to lack of information, the genomic era and the derived genetic data allows us to construct a more accurate relationship matrix than that derived from the pedigree. In fact the high quantity and quality genetic data generated from next generation sequencing technologies facilitate identity by descent (IBD) calculations and also us to compare long stretches of consecutive homozygous genotypes, so called runs of homozygosity, ROHs [41] identifying relationships between individuals not considered in pedigree based methods [35].

The bimodal distribution of EGV in breast cancer obtained here are similar to those calculated by Vazquez et al. [26] in skin cancer using BLUP based on pedigree or genomic information. Although these authors found better cancer prediction ability in terms of ROC area for the genomic information model than the pedigree model, 0.58 vs 0.63, the improvement in percentage terms was 8% and the genomic information was not used to construct a relationship matrix. On the other hand the economical expenses of a pedigree based method are lower than those which need genomic information.

The polygenic inheritance approach of BLUP provides a more realistic model of familial breast cancer in the absence of a known germline mutation than those that assume a single major allelic locus [14].

BLUP methodology is also used with shrinkage methods such Ridge, Lasso and Elastic Net [42,43] in order to reduce the high dimensionality of the data and to select significant variables. In fact BLUP works as a shrinkage method giving more importance to the genetic part of the model when heritability is high and penalizing the non-genetic terms of the model.

In the clinical practice an evaluating scheme of hereditary cancer can be established by setting-up a data base with all the pedigrees and clinical variables in order to calculate BLUP estimates for each individual and providing a reference measure when new affected families that need genetic counseling join the scheme. Even though male breast cancer does not appear to have a genetic component, they are evaluated and their genetic additive value is transmitted to the next generation. This is a relevant feature of BLUP, since other risk models assign the same value to a group of siblings [44].

Figure 3, illustrates this procedure where BLUP estimates within the same family discriminate risk between relatives which share the same number of affected relatives. As an example, in families 173,494, and 474, the third generation of cousins differs with regard to their genetic additive value. In family 173 in the 3rd generation there are three groups of cousins. The parents of two of them are affected. Descendants of 7118 and 7136

have the larger EGV (higher genetic risk), followed by the descendants of 7138 and 7121, and finally the descendants of 7137 and 7120 have the smallest expected genetic value but still have a genetic risk.

Figure 5 shows that as quantitative genetics highlighted, it is possible to calculate a value for offspring defined as the average value of the parents plus a random Mendelian noise factor, [39] which can be used in genetic counseling as an approximate prediction of EGV, giving a value to the clinician about the genetic cancer risk of the future offspring.

There is still a lot of speculation with regard to the management of families without a pathogenic germline mutation or carriers of variants of unknown significance in susceptibility genes, especially with regard to the age to start screening, the screening modality (mammography or MRI) and the recommendation of prophylactic surgery or preventative chemotherapy. These types of model could be most useful in these types of families for which the guidelines are not as clear. This information can help to prioritize individuals for screening and family members with a larger genetic additive values should be screened accordingly, in order to identify a cancer at a potentially curable stage.

The Gail model is used in the clinic to determine the probability of developing cancer within the next five years, whereas the BLUP method estimates lifetime genetic risk. We compared the risk assessment value of the Gail model with our model and a positive correlation was found between both models, indicating that they share the same underlying mechanism of cancer risk development but the risk values are interpreted differently. Gail model uses a given number of relatives in their estimation but BLUP is able to use the entire familial tree.

The Claus model assumes a single diallelic major locus as the underlying cause of susceptibility to breast cancer, whereas the BLUP model proposes a polygenic additive model and this is the reason why correlation between both models were low.

There are also other models to predict genetic cancer risk such as the BOADICEA model [45] which estimates based on age, whereas BLUP calculates genetics risk independently of age, sex or other confounders. Secondly, BOADICEA calculates a risk individual by individual, whereas BLUP evaluates all individuals at once given the possibility to have the EGVs of an entire population in a single step and saving time in the genetic counseling.

The BLUP method provides a novel application to the hereditary cancer setting that other models in use in cancer genetics do not offer. As presented in figure 7, BLUP can identify families with a large EGV, i.e. families with hereditary cancer and can help distinguish between those families that are likely to harbor high risk alleles (such as BRCA mutations) and families with low-medium risk alleles. The BLUP method can help us to identify families candidates to explore their genetic background looking for rarer polymorphisms via high density next generation sequencing. As well as deciphering the impact on risk of the many variants of unknown significance identified in *BRCA1* and *BRCA2* genes and others

BLUP model can be applied to other breast cancer populations or other cancer types in order to validate these results. This model also provides a reliable estimation of genetic cancer risk independently of environmental factors in a single step, assuming a polygenic underlying mechanism for cancer susceptibility, in contrast to the Gail and Claus models.

Conclusion

The results obtained give a reliable estimation of heritability different from zero in breast cancer and provide meaningful genetic additive values for each individual.

We have obtained a reliable estimation of heritability for breast cancer between 0.1- 0.2, different from zero, and meaningful additive values

of cancer in Minnesota Breast data set for each individual. These values alone or in combination with other methods improve cancer prediction in the hereditary cancer setting as well as the identification of novel genes/polymorphisms related with cancer and the assessment of the impact of variations on unknown significance on breast cancer risk. BLUP is able to incorporate clinical and pathological information in the estimations and consider a polygenic inheritance model instead of an autosomal dominant model.

BLUP provides an additional tool for use in hereditary cancer and estimates the extent of heritability of cancer, calculating an individual genetic risk of cancer in family members and an approximation of the genetic risk of future descendants. In addition this tool can be used to assess the genetic basis of hereditary cancer in these families, either due to high risk alleles for low-medium risk alleles.

Authors' Contributions

JCMA and LAGC designed the study and developed the statistical analysis tools and wrote the manuscript.

JCMA contributed to the statistical programming in R and LAGC test the posterior density of heritability.

JE and CGP provided expertise in clinical cancer for the application of the BLUP methodology to clinical cancer research and also wrote the manuscript.

All authors reviewed, commented and approved the manuscript.

Acknowledgment

The authors thank Marta Rava for her valuable comments in the manuscript.

Conflict of Interest

Author JC Martínez Avila, Author C Guillen-Ponce, Author J Earl and Author LA García-Cortés declare that they have no conflict of interest.

Data used in this work is free available at the R package kinship2. Data corresponds to Minnesota data breast cancer family study. Subjects in this data set are anonymized.

References

- Nagy R, Sweet K, Eng C (2004) Highly penetrant hereditary cancer syndromes. *Oncogene* 23: 6445-6470.
- Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, et al. (2014) Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention. *Cancer Prev Res* 7: 993-1001.
- Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, et al. (2013) Mutational landscape and significance across 12 major cancer types. *Nature* 502: 333-339.
- Bogdanova N, Helbig S, Dörk T (2013) Hereditary breast cancer: ever more pieces to the polygenic puzzle. *Hered Cancer Clin Pract* 11: 12.
- Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, et al. (2013) Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. *Breast Cancer Res* 15: R92.
- National Institute for Health and Care Excellence (2013) Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer.
- NCCN Guidelines (2016) National Comprehensive Cancer Network.
- Laloo F, Evans DG (2012) Familial Breast Cancer. *Clin Genet* 82: 105-114.
- Vahteristo P, Syrjäkoski K, Heikkinen T, Eerola H, Aittomäki K, et al. (2006) BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition. *Eur J Hum Genet* 14: 167-172.
- Loveday C, Turnbull C, Ruark E, Xicola RMM, Ramsay E, et al. (2012) Germline RAD51C mutations confer susceptibility to ovarian cancer. *Nat Genet* 44: 475-476.
- Thompson ER, Rowley SM, Sawyer S, kConFab, Eccles DM, et al. (2013) Analysis of RAD51D in Ovarian Cancer Patients and Families with a History of Ovarian or Breast Cancer. *PLoS One* 8: e54772.
- Antoniou AC, Easton DF (2003) Polygenic Inheritance of Breast Cancer: Implications for Design of Association Studies. *Genet Epidemiol* 25:190-202.
- Southey MC, Park DJ, Nguyen-Dumont T, Campbell I, Thompson E, et al. (2013) COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. *Breast Cancer Res* 15: 402.
- Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. *Cancer* 73: 643-651.
- Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, et al. (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 81: 1879-1886.
- Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, et al. (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. *J Natl Cancer Inst* 91: 1541-1548.
- Gail MH, Costantino JP (2001) Validating and Improving Models for Projecting the Absolute Risk of Breast Cancer. *J Natl Cancer Inst* 93: 334-335.
- Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA (2001) Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. *J Natl Cancer Inst* 93: 358-366.
- Euhus DM, Leitch AM, Huth JF, Peters GN (2002) Limitations of the gail model in the specialized breast cancer risk assessment clinic. *Breast J* 8: 23-27.
- Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, et al. (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. *J Med Genet* 45: 425-431.
- Parmigiani G, Chen S, Iversen ES, Friebel TM, Finkelstein DM, et al. (200) Validity of models for predicting BRCA1 and BRCA2 mutations. *Ann Intern Med* 147: 441-450.
- Saslow D, Boetes C, Burke W, Harms S, Leach MO, et al. (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 57: 75-89.
- Murphy CD, Lee JM, Drohan B, Euhus DM, Kopans DB, et al. (2008) The American Cancer Society guidelines for breast screening with magnetic resonance imaging: An argument for genetic testing. *Cancer* 113: 3116-3120.
- Henderson CR (1975) Best linear unbiased estimation and prediction under a selection model. *Biometrics* 31: 423-447.
- Speed D, Balding DJ (2014) MultiBLUP: improved SNP-based prediction for complex traits. *Genome Res* 29: 1550-1557.
- Vazquez AI, de los Campos G, Klimentidis YC, Rosa GJM, Gianola D, et al. (2012) A comprehensive genetic approach for improving prediction of skin cancer risk in humans. *Genetics* 192: 1493-1502.

27. Sellers TA, King RA, Cerhan JR, Chen PL, Grabrick DM, et al. (1999) Fifty-year follow-up of cancer incidence in a historical cohort of Minnesota Breast Cancer Families. *Cancer Epidemiol Biomarkers Prev* 8: 1051-1057.
28. Grabrick DM, Cerhan JR, Vierkant RA, Therneau TM, Cheville JC, et al. (2003) Evaluation of familial clustering of breast and prostate cancer in the Minnesota Breast Cancer Family Study. *Cancer Detect Prev* 27: 30-36.
29. Sinnwell JP, Therneau TM, Schaid DJ (2014) The kinship2 R Package for Pedigree Data. *Hum Hered* 78: 91-93.
30. R Development Core Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
31. Hadfield J (2010) MCMC methods for multi-response generalized linear mixed models: the MCMCglmm R package. *J Stat Softw* 33: 1-22.
32. Stekhoven DJ, Bühlmann P (2012) Missforest-Non-parametric missing value imputation for mixed-type data. *Bioinformatics* 28: 112-118.
33. Sing T, Sander O, Beerenwinkel N, Lengauer T (2005) ROCr: Visualizing classifier performance in R. *Bioinformatics* 21: 3940-3941.
34. Fisher RA (1918) The Correlation between Relatives on the Supposition of Mendelian Inheritance. *Trans R Soc Edinburgh* 52: 399-433.
35. Malécot G (1948) *Les mathématiques de l'hérédité*. Cie M et, editor, Paris.
36. García-Cortés LA, Cabrillo C, Moreno C, Varona L (2001) Hypothesis testing for the genetic background of quantitative traits. *Genet Sel Evol* 33: 3-16.
37. Sorensen D, Andersen S, Gianola D, Korsgaard I (1995) Bayesian inference in threshold models using Gibbs sampling. *Genet Sel Evol* 27: 229-249.
38. Heidelberger, P Welch P (1981) A spectral method for confidence interval generation and run length control in simulations. *Comm ACM* 24: 233-245.
39. Falconer DS, Mackay TFC (1998) *Introduction to Quantitative Genetics*, 4th Edition. Essex, England: Longman Group Ltd.
40. Forni S, Aguilar I, Misztal I (2011) Different genomic relationship matrices for single-step analysis using phenotypic, pedigree and genomic information. *Genet Sel Evol* 43: 1.
41. Luan T, Yu X, Dolezal M, Bagnato A, Meuwissen T (2014) Genomic prediction based on runs of homozygosity. *Genet Sel Evol* 46: 64.
42. Shen X, Alam M, Fikse F, Rönnegård L (2013) A novel generalized ridge regression method for quantitative genetics. *Genetics* 193: 1255-1268.
43. Endelman JB (2011) Ridge Regression and Other Kernels for Genomic Selection with R Package rrBLUP. *Plant Genome J* 4: 250-255.
44. Kastrinos F, Steyerberg EW, Mercado R, Balmaña J, Holter S, et al. (2011) The PREMM1,2,6 model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. *Gastroenterology* 140: 73-81.
45. Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, et al. (2014) BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. *Br J Cancer* 110: 535-545.